The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Just relax. Wait 3 weeks and we will find out.
Everyone has been burnt badly from this stock, so we know we have to keep calm and keep our expectations low. However, if there is some good data that is statistically significant we might be able to attract a joint venture or takeover.
If we attract a joint venture, then we get to partner up with big pharma who will get this drug over the line.
We only have to wait 3 weeks until we find out what’s in store.
It looks like there might be some promising data to be presented which could lead to a rerate in the SP and possible joint venture or platform trial.
Let’s try to remain calm, neither ramping or deramping, keep our expectations very relaxed and then we may be pleasantly surprised with the outcome in a few weeks.
I think it’s important not to raise hopes too much.
Besides, we can see from the daily peaks and troughs of the graph that this stock is being heavily day traded every single day.
Costs, we know it’s on its knees.
I understand your frustration (I feel it too), but there isn’t anything to gain by being negative.
Sure, we know there are some posters ramping it up the whole time still, any little piece of info, just ignore them then. But look at the company and what they are saying.
We specifically had an RNS mentioning the P2 results within a specific cohort. Within the RNS it said that SPRINTER’s results of that cohort will be discussed at the thoracic conference. This is actually a little bit of good news.
The company isn’t going to RNS this (at least I hope not) and make everyone aware of the upcoming presentation at the thoracic conference and then have nothing to say. They have specifically mentioned that SPRINTER details will be discussed, so this also eliminates the possibility of them just revisiting old phase 2 SG016 ground at the conference as well.
We may have an RNS beforehand as well. Either way, there will be a development come the conference.
Whatever development it could be may be enough to get us on to a platform trial, or a joint venture with big pharma.
I’ve been heavily critical of the company, particularly Marsden. But at least with this RNS we are seeing the company telling us they are moving forward and trying to push further along.
I said it a couple of weeks ago, when I held out an olive branch for all members (although some still seem to want to squabble), but we are all in this together after investing and losing so much. We are the remaining holders that are clinging on and not selling at a huge loss. Let’s give Marsden and the team a chance to get the show back on the road again (I specifically wrote they deserve six months). There is every right to be sceptical, after we have been burnt so badly, but no point being negative just a few weeks away from whatever news they want to discuss.
Brand, if Jordan has been brought in to bend ears in DC then I’d say he’s worth any money we spend on him.
But the article that mentions him working with us was on February 18th. The SPRINTER results were announced on 21st. So unless Synairgen knew about the disaster a week before the RNS and spoke to Ray immediately, then the article was published a few days later, it wouldn’t fit.
I’m more optimistic that something can come from the upcoming annual thoracic conference.
Maybe Brooke can tell us if the company are still working with Jordan. If they are, then your theory could be right.
Surely Synairgen knew of these charts over a year ago?
They are from the SG016 P2 trial.
Anyhow, if placebo gave 61% chance of stopping progression to severe disease and SNG001 have 83% chance of stopping progression to severe disease, the SNG001 drug gave a 22 point higher chance of saving someone over placebo.
OR could be read as SNG001 gives 35% more efficacy than placebo.
Agreed, this was in line with the SPRINTER result as well (although didn’t have the P value to help us).
At least this is an encouraging observation and finding.
Hopefully it’s going to lead somewhere positive for the company.
I would have thought that Ray Jordan would only have worked with us if our drug had passed its P3 trial?
Then Jordan would be used for marketing and links to governments and pharma world?
Maybe I’m wrong, but what can Jordan do with a drug that doesn’t have EUA or a successful P3 trial?
Maybe if we can get on to a platform trial then he will work with us. But either way, what’s the point of paying this guy to work with us if we don’t have a product out there? Better to save our money and wait until we get he product out, or big pharma comes along to help us get it out (or buys us).
https://www.fool.co.uk/2022/04/25/whats-next-for-the-synairgen-lon-sng-share-price/
Actually quite fair assessment of the situation.
Interestingly it was Motley fool who called us a ‘hype train’ when we were doing well.
https://conference.thoracic.org/speakers/resources/2021/disclosure.pdf
A 50 page document. But just a brief scan of names and companies involved will show plenty of people from AZ, GSK, Eli Lily, Sanofi, Regeneron, Gilead and of course Pfizer.
So we know that all the big pharma boys will be there.
We just have to hope that Synairgen have some new positive data from the SPRINTER deep dive to show them.
Only 3 weeks to go now, then we might get some positive news. We just have to hope they have something new from SPRINTER.
A joint venture with one of the big boys would change everything.
Size82, I hope so.
If there are some nice chunks of extra data from SPRINTER with the specific cohort they were mentioning in the SG016 presentation last week and they are revealed at the upcoming May conference, maybe it’ll be enough for us to partner with pharma for a joint venture?
This seems to be what they’re going for.
I will be accused of deramping, but it doesn’t appear that we have enough for the company to initiate an EUA application. Unless it’s hidden in the data they will release at the May conference and they’re waiting.
If they manage to get a joint venture with big pharma, I’d certainly take that.
In fact, it would be worth holding on to your shares rather than selling at 70p/£1, if big pharma get involved then they will manage to take this drug over the line and we will be taken over. Certainly appears that Synairgen are aiming to travel down this route, albeit no guarantees that any big pharma company will jump on board.
I’ve read most the responses on here and it seems only Welsh falcon mentioned it.
The presentation they gave was about the SG016 Phase 2 trial where results were released in July 2020.
This presentation had nothing to do with SPRINTER or ACTIV2.
Basically Synairgen went to an event and did a presentation on the old P2 data at the start of the pandemic which was successful, probably to try and entice governments or Pharma to help us with a new trial.
At least in the second part of the RNS they said SPRINTER detailed findings will be discussed at the May conference. So we ‘might’ see some further science in May.
It seems the team are still clutching on to their P2 SG016 trial results of 2020 which everyone already knows about. They’re trying to attract pharma or a government to join and give us a free trial. Big pharma would be better because they know how to get this drug over the line.
Squabble, squabble, squabble, bla bla blah.
You and everyone else has lost tens of thousands and you want to create imaginary arguments on a stock forum for a company that has lost everyone around 90% (tens of thousands and in some cases hundred of thousands).
Does it really need to be said? Grow up.
Clearly you’re very young, or don’t have many friends, do yourself a favour and go out on the ****, check out a local lap dancing bar or hire a hooker. Enjoy your life rather than trying desperately to squabble squabble squabble on an internet message board, particularly on a section dedicated to this useless company.
Even daneeka says the same thing I was saying six months ago. The drugs great, the company is useless.
For all new investors use this stock as a gamble, if the drug can be taken out of Synairgens hands then you’ll make money, if it stays in Synairgen’s hands then you can listen to the usual mob on here ramping it up, but it will never come to market.
Now, I finish in the city early today, so I’m going for drinks with the boss at the Ned. Enjoy your weekends and try to stop obsessing over Synairgen or people on Internet forums.
Tbh I don’t think it matters when it’s released.
We are going to know by 16th May what the deal is anyway.
If it’s 30th April or a couple days before 16th May, it’s less than a month away.
However, as we learnt regarding 21st Feb, there is no guarantee that the RNS will be positive.
Given that we are due some positive karma, in a fair world Synairgen will be able to report some good findings from the DD or be able to RNS the ACTIV2 data and a new development. If that does happen, we will get a rerate in SP.
There is one thing that I have been thinking, although I don’t want to get hopes up. I wonder if Synairgen have already been in talks behind the scenes with big pharma and this might have been a reason why Polygon have been buying up more shares (other than lowering their average).
Anyway, give it a month and we will find out what’s happening, either something moving forward like a JV, platform trial or EUA application, or whether the company is just totally fing useless.
Size I think you are spot on there.
With a bit of luck, RM and his merry men are thinking logically, it’s 2k a pop, therefore if they can demonstrate its efficacy and worth in the high risk patients then it justifies its high price, EUA or further trials.
It also justifies hospitals stocking it and distribution.
Let’s just hope that this is what Marsden has in mind.
The pal:
‘with a team of statisticians working on the data for eight weeks, the company must have received a substantial amount of feedback by now.’
You’d like to think so, but it took four months for Omicron IV results to come back and the data analysed.
I’ve no idea what data will come back from this deep dive, hopefully something good. But I think it’ll be a longer wait. Hopefully they’ll be able to present something at this coming conference and could RNS the results a few days before. I would imagine they’re working to the deadline of having some data ready by the time of the conference. So only another four weeks to go.
Surely they can’t be going to the conference without anything new to contribute? That would just be adding insult to injury for shareholders. Let’s wait and see.
Tatty, that’s a great post, sums up my frustration and anger which led me to trash talk this stock on here a couple weeks back.
But we are just venting frustration.
In the end, there MIGHT be something to salvage from this trial and it could allow a much more experienced team to takeover control of a trial.
We do have all IV results and they show SNG001 works on all variants. This is positive.
We have our P2 data and hopefully getting ACTIV2 data as well. We don’t yet have the long covid data, although it has been ample time to retrieve the long covid data by now and we’ve heard nothing from Synairgen yet (maybe that’s a good thing, or they’re learning, if the long covid data comes back rubbish then I’d much rather they don’t bother releasing it and just wait until the end of the deep dive).
Maybe we can get a big pharma company to help us, if Marsden et co have the ambition to do this. Otherwise yeah, it’s really going to be a dead company.
We should find out in the next few months what way it’s going, if there is big pharma interest then I think in the long run we will at least get our money back. If there is no big pharma interest or other platform trial then even the biggest SNG cheerleaders on here will probably admit that it’s curtains for us.
Wait these few months and see what can happen.
Example, Adagio and NRX both looked finished, they have both announced that they have applied for EUA.
If they have, we could potentially do it too.
Tommy, maybe (we can only hope) they’re trying to make the case for the 36%.
But there were other initial observations as well. The main one being what the RNS stated, ‘We think the steroids in the SOC affected the treatment’.
So they might be able to look at the early data from pre futility marker and pull out much better results when compared to later data when more steroids such as dexamethasone were being used.
Either way, it would be nice to get some answers as to how they so badly fudged it.
If they are focussing on the 36% then it means they will try to push for a new platform trial at least, preferably a JV. I think it was Kevin who said that despite a possibility filing for EUA, Synairgen haven’t mentioned this at all, so probably highly unlikely.
That said, Adagio did not mention applying for EUA either, after their in vitro omicron failure.
I suppose they will also be trying to lure in big pharma by showing the in vitro results and the treatments variant agnostic ability.
If we can somehow attract a big pharma company to help us with JV and sponsor a new phase 3 trial then it’ll be a good time to make a top up and hold for a couple of years, with knowledge that a much more credible and safer pair of hands will be in the driving seat.
Good data from the initial first half of SPRINTER also could be enough to tempt big pharma for a TO or JV.
There is still a lot to play for, particularly if the long covid data is good.
However I think after Marsden’s last interview and the previous RNS’s where they speak of finding new platform trials it just feels like the team are throwing their hands in the air ‘Oh well, our P3 didn’t work, but let’s do another trial’, as opposed to showing any determination to apply for EUA based on deep dive and A2P2 to get this thing over the line.
The bottom line is that if deep dive can salvage any good data (and relevant data) and be combined with A2P2 data then it will certainly be enough for the NIH to put together a P3 trial for us. But also it might be enough for a pharma company to make a bid, particularly if they are getting a free P3 NIH trial thrown in as well.